Is GSK a takeover target post OTC split?

GSK at 33.72 very near a ten year low. Next year they will spin out the OTC business which is 30% of revenue.

Will the stock got to 23.60 then?

If so would it be an attractive target for a group of Pharma Companies to swoop in and chop up?

Vaccines are a gem they go one place

Respiratory makes money it goes another place

ViiV could be setup as a stand alone.

The remainder , Oncology sales and some very interesting but young immuno and oncology project go to the highest bidder.

Thoughts?

 

Pfizer

 

Google. They are already in the business.

Verily Life Sciences
Calico Labs
Galvani Bioelectronics, which is a Google+GSK partnership.

 

It's just a matter of time folks. Enjoy your 1 week of pay for every year of service.